Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803–827

2009 ◽  
Vol 15 (3) ◽  
pp. 555-559
Author(s):  
Wojciech Bartminski
Keyword(s):  
Lung Cancer ◽  
Economic Analysis ◽  
Supportive Care ◽  
Small Cell Lung Cancer ◽  
Best Supportive Care ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
Third Line ◽  
Third Line Treatment

Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis

Lung Cancer ◽  
2012 ◽  
Vol 76 (3) ◽  
pp. 472-477 ◽  
Author(s):  
Ian Cromwell ◽  
Kimberly van der Hoek ◽  
Suzanne C. Malfair Taylor ◽  
Barbara Melosky ◽  
Stuart Peacock
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Supportive Care ◽  
Best Supportive Care ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
Effectiveness Analysis ◽  
Third Line ◽  
Third Line Treatment

Second and third line treatment in non-small cell lung cancer

2009 ◽  
Vol 71 (2) ◽  
pp. 117-126 ◽  
Author(s):  
Adolfo Favaretto ◽  
Giulia Pasello ◽  
Cristina Magro ◽  
Clorinda Schettino ◽  
Cesare Gridelli
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
Third Line ◽  
Third Line Treatment
Sign in / Sign up

Export Citation Format

Share Document